Five- and 10-year estimates of absolute and relative survival of patients with CLL by age group, sex, and calendar period
| Age, sex . | Calendar period . | Increase* . | P† . | |||
|---|---|---|---|---|---|---|
| 1980-1984 . | 2000-2004 . | |||||
| PE . | SE . | PE . | SE . | |||
| 5-year absolute survival | ||||||
| All | 54.2 | 0.9 | 60.2 | 0.8 | +6.0 | <.0001 |
| 15-59 | 76.6 | 1.6 | 81.0 | 1.3 | +4.4 | <.001 |
| 60-69 | 66.4 | 1.5 | 74.5 | 1.4 | +8.1 | <.0001 |
| 70-79 | 49.8 | 1.6 | 58.5 | 1.4 | +8.7 | <.0001 |
| 80+ | 24.0 | 1.6 | 30.0 | 1.5 | +6.0 | <.001 |
| Men | 51.7 | 1.1 | 59.7 | 1.0 | +8.0 | <.001 |
| Women | 57.6 | 1.3 | 60.9 | 1.2 | +3.3 | .008 |
| 10-year absolute survival | ||||||
| All | 27.8 | 0.9 | 34.8 | 0.7 | +7.0 | <.001 |
| 15-59 | 46.5 | 2.3 | 58.9 | 1.7 | +12.4 | <.001 |
| 60-69 | 38.1 | 1.9 | 48.1 | 1.6 | +10.0 | <.001 |
| 70-79 | 20.8 | 1.6 | 30.0 | 1.3 | +9.2 | <.001 |
| 80+ | 6.7 | 1.1 | 6.4 | 0.8 | −0.3 | .011 |
| Men | 24.5 | 1.2 | 33.6 | 1.0 | +9.1 | <.001 |
| Women | 32.2 | 1.5 | 36.4 | 1.2 | +4.2 | .019 |
| 5-year relative survival | ||||||
| All | 69.2 | 1.1 | 75.2 | 0.9 | +6.0 | <.001 |
| 15-59 | 80.8 | 1.7 | 84.1 | 1.3 | +3.3 | .004 |
| 60-69 | 75.8 | 1.8 | 82.7 | 1.6 | +6.9 | .003 |
| 70-79 | 66.3 | 2.1 | 74.3 | 1.8 | +8.0 | <.001 |
| 80+ | 48.4 | 3.1 | 56.9 | 2.8 | +8.5 | .008 |
| Men | 67.2 | 1.5 | 74.4 | 1.2 | +7.2 | <.001 |
| Women | 71.9 | 1.6 | 76.4 | 1.5 | +4.5 | .002 |
| 10-year relative survival | ||||||
| All | 46.0 | 1.5 | 55.4 | 1.2 | +9.4 | <.001 |
| 15-59 | 53.1 | 2.6 | 64.5 | 1.8 | +11.4 | <.001 |
| 60-69 | 52.6 | 2.6 | 62.7 | 2.1 | +10.1 | .021 |
| 70-79 | 42.1 | 3.2 | 55.0 | 2.3 | +12.9 | <.001 |
| 80+ | 32.7 | 5.0 | 29.6 | 3.6 | −3.1 | .058 |
| Men | 42.0 | 2.0 | 53.5 | 1.5 | +11.5 | <.001 |
| Women | 51.2 | 2.3 | 58.1 | 1.8 | +6.9 | .003 |
| Age, sex . | Calendar period . | Increase* . | P† . | |||
|---|---|---|---|---|---|---|
| 1980-1984 . | 2000-2004 . | |||||
| PE . | SE . | PE . | SE . | |||
| 5-year absolute survival | ||||||
| All | 54.2 | 0.9 | 60.2 | 0.8 | +6.0 | <.0001 |
| 15-59 | 76.6 | 1.6 | 81.0 | 1.3 | +4.4 | <.001 |
| 60-69 | 66.4 | 1.5 | 74.5 | 1.4 | +8.1 | <.0001 |
| 70-79 | 49.8 | 1.6 | 58.5 | 1.4 | +8.7 | <.0001 |
| 80+ | 24.0 | 1.6 | 30.0 | 1.5 | +6.0 | <.001 |
| Men | 51.7 | 1.1 | 59.7 | 1.0 | +8.0 | <.001 |
| Women | 57.6 | 1.3 | 60.9 | 1.2 | +3.3 | .008 |
| 10-year absolute survival | ||||||
| All | 27.8 | 0.9 | 34.8 | 0.7 | +7.0 | <.001 |
| 15-59 | 46.5 | 2.3 | 58.9 | 1.7 | +12.4 | <.001 |
| 60-69 | 38.1 | 1.9 | 48.1 | 1.6 | +10.0 | <.001 |
| 70-79 | 20.8 | 1.6 | 30.0 | 1.3 | +9.2 | <.001 |
| 80+ | 6.7 | 1.1 | 6.4 | 0.8 | −0.3 | .011 |
| Men | 24.5 | 1.2 | 33.6 | 1.0 | +9.1 | <.001 |
| Women | 32.2 | 1.5 | 36.4 | 1.2 | +4.2 | .019 |
| 5-year relative survival | ||||||
| All | 69.2 | 1.1 | 75.2 | 0.9 | +6.0 | <.001 |
| 15-59 | 80.8 | 1.7 | 84.1 | 1.3 | +3.3 | .004 |
| 60-69 | 75.8 | 1.8 | 82.7 | 1.6 | +6.9 | .003 |
| 70-79 | 66.3 | 2.1 | 74.3 | 1.8 | +8.0 | <.001 |
| 80+ | 48.4 | 3.1 | 56.9 | 2.8 | +8.5 | .008 |
| Men | 67.2 | 1.5 | 74.4 | 1.2 | +7.2 | <.001 |
| Women | 71.9 | 1.6 | 76.4 | 1.5 | +4.5 | .002 |
| 10-year relative survival | ||||||
| All | 46.0 | 1.5 | 55.4 | 1.2 | +9.4 | <.001 |
| 15-59 | 53.1 | 2.6 | 64.5 | 1.8 | +11.4 | <.001 |
| 60-69 | 52.6 | 2.6 | 62.7 | 2.1 | +10.1 | .021 |
| 70-79 | 42.1 | 3.2 | 55.0 | 2.3 | +12.9 | <.001 |
| 80+ | 32.7 | 5.0 | 29.6 | 3.6 | −3.1 | .058 |
| Men | 42.0 | 2.0 | 53.5 | 1.5 | +11.5 | <.001 |
| Women | 51.2 | 2.3 | 58.1 | 1.8 | +6.9 | .003 |